Explore the words cloud of the SMIMS project. It provides you a very rough idea of what is the project "SMIMS" about.
The following table provides information about the project.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
|Coordinator Country||United Kingdom [UK]|
|Total cost||142˙050 €|
|EC max contribution||142˙050 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2018-08-01 to 2020-01-31|
Take a look of project's partnership.
|1||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||coordinator||142˙050.00|
We aim to demonstrate the disruptive commercial and societal potential of interferometric scattering microscopy for mass spectrometry of single biomolecules in solution. The PoC grant will be used to produce a near-market ready prototype and implement the required software modifications expected of a commercial device, to demonstrate that the technology is sufficiently robust to warrant venture capital funding for our spin-out company. Our early discussions with both pharma and instrument manufactueres have highlighted a need for more in-depth application of our technique. The novelty of our approach requires both demonstration and testing on a broad range of potential analytes and environments, which is why we require a portable instrument, that not only enables on-site testing, but also on-site demonstration in a non-university research environment. Similarly, there is a clear and pressing need to produce more intuitive and clearly commercially viable software to unlock the full potential of our technology. Data from these experiments will help define our final product(s) and to translate this research into a viable package for raising venture capital. The development of a novel, broadly accessible technology enables new avenues for screening potential drug candidates that could be used to further our understanding of drug interactions at the molecular level. The economic benefits will, therefore, be realised primarily through the pharmaceutical, healthcare and allied industries as well as the bioanalytical industry, through increased sales of instruments. All will have a considerable impact on the European economy. In addition to drug-discovery-related advances, our technology has the potential to transform cholesterol classification and change current approaches to cancer screening, through its intrinsic single molecule sensitivity.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMIMS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SMIMS" are provided by the European Opendata Portal: CORDIS opendata.
The Enemy of the Good: Towards a Theory of Moral ProgressRead More
Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin DomainsRead More
Discovery and Characterization of Hydrogen-Based High-Temperature SuperconductorsRead More